We are committed to finding effective treatment for life-threatening infectious diseases.
A Game Changer in Antibacterials Treatment for Gram-negative bacteria, Ultimate Target of N-Rephasin® Technology
Eco-friendly, no Side-effects, Unique mode of action. Bacteriophages and Antibiotic Resistance in Bacteria
New Generation of Heme-Iron (Porphyrin-Fe) Novel concept iron deficiency anemia therapeutic agent
Arixa Pharmaceuticals™, Inc., a company dedicated to developing next-generation oral antibiotics for drug-resistant Gram-negative infections today announced that Pfizer’s Hospital Business has agreed to acquire Arixa. Arixa’s lead compound, ARX-1796, is an oral prodrug of avibactam, a beta lactamase inhibitor (BLI) that was FDA-approved in 2015 as part......
iNtRON Biotechnology has developed a LiliF™ GBN COVID-19 IgG Rapid Kit. LiliF™ GBN COVID-19 IgG Rapid Kit is a lateral flow chromatographic immunoassay for the detection of anti-SARS-CoV-2 IgG antibodies in human whole blood, serum or plasma. It is intended to be used by professionals......
In most recent news, Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company, announced that the Department of Defense (DoD) has awarded them $9.8 million for the research development of multiple Phase-1 high-priority, bacteriophage-based vaccine candidates against SARS-CoV-2. APT research contract with the DoD will only advance......
iNtRON Bio has been focusing on the R&D investment since its foundation and accelerate development speed after the IPD in KOSDAQ. We are aiming for the ‘global R&D company’ ; and promoting the value of the company focused on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies in phases.
